19th International Congress on Neutron Capture Therapy Granada, Spain, September 27th - October 1th, 2021





Accelerator-based boron neutron capture therapy: *in vivo* experiments.

V. Kanygin¹, A. Kasatova^{1, 2}, A. Kichigin¹, E. Zavjalov¹, I. Razumov¹, R. Muhamadiyarov¹, S. Taskaev^{1, 2}

> ¹ Novosibirsk State University, Novosibirsk, Russia ² Budker Institute of Nuclear Physics, Novosibirsk, Russia

The report is about an assessment of a beam at an accelerator neutron source at Budker Institute of Nuclear Physics and its possible application on glioblastoma tumor. An evaluation of the efficacy of boron neutron capture therapy on heterotopic glioblastoma U87 MG in SCID mice using different boron containing drugs was carried out. Accumulation of ¹⁰B in tumor and normal tissues was detected using atomic emission spectrometer ICPE-9820 (Shimadzu, Japan). Tumor growth was significantly slower in all irradiated groups from the 7th day after BNCT compared to untreated control group. The differences between experimental groups became significant from the 50th day after BNCT. Liposomal BSH showed better long-term results compared to BPA and non-liposomal BSH.

The study was carried out with the support of the Russian Foundation for Basic Research (grant No. 18-29-01007) using the equipment of the Center for Genetic Resources of Laboratory Animals, Institute of Cytology and Genetics, supported by the Ministry of Education and Science of Russia (Unique identifier of the project is RFMEFI62117X0015). Irradiation at the neutron source was supported by the Russian Science Foundation (grant № 19-72-30005).

Keywords:

boron neutron capture therapy, accelerator based epithermal neutron source; boronophenylalanine, sodium borocaptate, liposomal borocaptate, SCID mice with subcutaneous xenografts of human glioblastoma U87 MG.